This inventor holds 2 USPTO granted patents. Top assignee: Polaris Pharmaceuticals, Inc.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Innovations by Hui-Fen Liu in Cancer Therapy
Introduction
Hui-Fen Liu is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer therapy, particularly through his innovative methods related to arginine deprivation therapy. With a total of 2 patents, Liu's work is paving the way for advancements in cancer treatment.
Latest Patents
Hui-Fen Liu's latest patents include groundbreaking methods for predicting responses to arginine deprivation therapy based on plasma arginine levels in cancer patients. This method involves determining the plasma level of arginine in a subject and subsequently administering arginine deprivation therapy, either alone or in combination with an anti-cancer agent, based on the determined plasma level. The anti-cancer agents may include FOLFOX, docetaxel, cisplatin, pemetrexed, pembrolizumab, or a combination thereof. Another significant patent focuses on methods and kits for identifying subjects who are responsive to arginine deprivation therapy.
Career Highlights
Hui-Fen Liu is currently associated with Polaris Pharmaceuticals, Inc., where he continues to develop innovative solutions for cancer treatment. His work is characterized by a strong emphasis on research and practical applications that can significantly impact patient care.
Collaborations
Liu collaborates with esteemed colleagues, including Hung-Wen Chen and Chau-Ting Yeh, who contribute to the research and development efforts in the field of cancer therapy.
Conclusion
Hui-Fen Liu's contributions to cancer therapy through his innovative patents demonstrate his commitment to improving treatment outcomes for patients. His work continues to inspire advancements in medical research and therapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile